volume 9, issue 3, P955-963 2017
DOI: 10.18632/aging.101202
View full text
|
|
Share
Yi Zhu, Ewald J. Doornebal, Tamar Pirtskhalava, Nino Giorgadze, Mark Wentworth, Heike Fuhrmann-Stroissnigg, Laura J. Niedernhofer, Paul D. Robbins, Tamara Tchkonia, James L. Kirkland

Abstract: Senescent cells accumulate with aging and at sites of pathology in multiple chronic diseases. Senolytics are drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro-survival pathways that enable senescent cells to resist the pro-apoptotic, pro-inflammatory factors that they themselves secrete. Reducing senescent cell burden by genetic approaches or by administering senolytics delays or alleviates multiple age- and disease-related adverse phenotypes in preclinical models. Re…

expand abstract